Does WellCare Cover Metformin?

What Is WellCare and Which Plans Offer Drug Coverage?

WellCare Health Plans, now a subsidiary of Centene Corporation, administers Medicare Advantage (Part C) and standalone Medicare Part D Prescription Drug Plans (PDPs) across dozens of states. Each plan type has its own formulary, and formularies are updated every January 1.

Standalone Part D Plans vs. Medicare Advantage

WellCare offers both standalone PDPs (sold alongside original Medicare Parts A and B) and Medicare Advantage plans that bundle medical and drug coverage. Both product lines must comply with CMS formulary requirements under 42 CFR Part 423, which mandate that Part D sponsors cover at least two drugs in most therapeutic categories. The CMS 2025 Part D Final Rule extended protections around cost-sharing for generic drugs on lower tiers.

Metformin falls under the antidiabetic biguanide class. Because it is one of the most prescribed generic drugs in the United States, covering approximately 92 million prescriptions annually according to IQVIA data referenced by the FDA, virtually every Part D formulary includes it.

Why Formularies Change Year to Year

CMS requires Part D sponsors to file formulary changes with the agency before October 1 each year for the following plan year. A drug that was Tier 1 in 2024 could move to Tier 2 in 2025, changing your out-of-pocket cost. The CMS Medicare Prescription Drug Benefit Manual, Chapter 6 outlines how sponsors must notify enrollees of mid-year formulary changes at least 60 days in advance or at the point of sale.

How Metformin Is Classified on the WellCare Formulary

Most WellCare Part D plans place metformin immediate-release (IR) on Tier 1 and metformin extended-release (ER) on Tier 1 or Tier 2, both as preferred generics. A small number of high-deductible WellCare plan variants may apply the Part D deductible before cost-sharing begins, which can raise your first-fill cost in January each year.

Metformin IR vs. ER Tier Placement

Metformin IR (500 mg, 850 mg, and 1,000 mg tablets) is the lowest-cost option. Metformin ER (500 mg, 750 mg, and 1,000 mg extended-release tablets) reduces gastrointestinal side effects in approximately 20 to 25 percent of patients who cannot tolerate IR, based on data from the University Group Diabetes Program follow-up studies archived at PubMed. When ER is placed on Tier 2 rather than Tier 1, the typical copay difference is $3 to $7 per fill.

The branded Glucophage formulation is rarely covered on WellCare formularies because the generic is therapeutically equivalent per FDA Orange Book listing NDA 021202.

Quantity Limits and Step Therapy

WellCare may impose quantity limits on metformin ER at higher doses. The maximum approved daily dose is 2,550 mg for IR and 2,000 mg for most ER formulations per the FDA-approved prescribing information for metformin HCl. Quantities beyond those limits may trigger a prior authorization review, not because the drug is restricted per se but because the dose exceeds the labeled maximum.

Step therapy requirements for metformin are uncommon because it is the first-line agent recommended in the American Diabetes Association Standards of Care in Diabetes, Section 9 (2024). The ADA states: "Metformin, if not contraindicated and if tolerated, is the preferred initial pharmacologic agent for the treatment of type 2 diabetes."

How Much Does Metformin Cost Under WellCare in 2025?

Cost-sharing depends on the coverage phase you are in: the deductible phase, the initial coverage phase, or the catastrophic coverage phase. Starting January 1, 2025, the Inflation Reduction Act eliminated the coverage gap (donut hole) and capped out-of-pocket drug costs at $2,000 per year under CMS IRA Part D Redesign.

Deductible Phase

WellCare plans that carry the standard Part D deductible (set at $590 in 2025 per CMS 2025 Part D parameters) may require you to pay the full negotiated price for metformin until the deductible is met. Many WellCare plans exempt Tier 1 and Tier 2 generics from the deductible entirely. Check your plan's Summary of Benefits to confirm.

Initial Coverage Phase

Once past the deductible (if any applies), copays for Tier 1 generics on WellCare plans typically run $0 to $5 for a 30-day supply and $0 to $15 for a 90-day mail-order supply. Tier 2 copays generally fall between $5 and $15 for 30 days. These figures are consistent with the CMS national average for preferred generic cost-sharing reported in the 2024 Medicare Part D Spotlight (KFF).

Catastrophic Phase

After reaching the $2,000 out-of-pocket cap in 2025, all covered Part D drugs, including metformin, are available at $0 cost-sharing for the remainder of the calendar year. Metformin's low unit cost means most patients will never approach the cap on this drug alone.

Prior Authorization for Metformin Under WellCare

Standard doses of metformin for type 2 diabetes generally do not require prior authorization on WellCare formularies. PA is most likely to be required in three specific scenarios.

When PA May Be Triggered

1. Off-label use for prediabetes. The Diabetes Prevention Program (DPP) Outcomes Study (DPPOS) demonstrated that metformin 850 mg twice daily reduced progression from prediabetes to type 2 diabetes by 31 percent over 10 years (N=3,234, P<0.001 vs. Placebo). Some payers require documentation that lifestyle intervention was attempted first before covering metformin for an A1C between 5.7 and 6.4 percent.

2. Off-label use for polycystic ovary syndrome (PCOS). The Endocrine Society Clinical Practice Guideline on PCOS (2023) recommends metformin as a treatment option for metabolic features of PCOS, yet Part D coverage for a non-diabetes ICD-10 code may prompt PA.

3. Doses exceeding labeled maximums. Any prescription written for more than 2,550 mg/day will likely require PA and clinical justification.

How to Submit a PA Request

Your prescriber submits a PA request directly to WellCare using the plan's PA form or through the CoverMyMeds electronic PA platform. WellCare must respond to standard PA requests within 72 hours and to expedited (urgent) requests within 24 hours, per 42 CFR 423.568.

Metformin for Longevity and Anti-Aging: Coverage Considerations

Metformin has attracted significant attention as a potential longevity drug. The TAME (Targeting Aging with Metformin) trial, a 6-year multicenter RCT funded by the American Federation for Aging Research, is testing metformin 1,500 mg/day in adults aged 65 to 79 without diabetes to see whether it delays age-associated diseases. The trial enrolled 3,000 participants and results are expected in 2026 to 2027.

Does WellCare Cover Metformin for Longevity?

Short answer: not directly. Medicare Part D covers drugs only for medically accepted indications, defined as FDA-approved uses or uses supported by one of the compendia listed in 42 USC 1395x(t)(2). "Longevity" is not yet a recognized indication. Until TAME publishes primary endpoints and the ADA or another major compendia adds the indication, WellCare and all other Part D plans will likely deny claims billed under a longevity ICD-10 code.

Patients in longevity protocols who also carry a type 2 diabetes or prediabetes diagnosis will generally have coverage because those indications are valid. The ADA 2024 Standards of Care states that metformin may be considered for high-risk prediabetes patients, particularly those with BMI >35, age <60, or prior gestational diabetes.

AMPK Activation and the Mechanistic Basis for Longevity Interest

Metformin activates AMP-activated protein kinase (AMPK) via inhibition of mitochondrial complex I, reducing hepatic glucose output. Research published in Nature Communications (2016) identified that metformin's activation of AMPK in C. Elegans extended median lifespan by approximately 36 percent by altering the folate and methionine cycles. Human translation remains investigational.

A 2022 observational study published in Aging Cell compared diabetic patients on metformin to non-diabetic controls and found that metformin users had lower all-cause mortality (hazard ratio 0.85, 95% CI 0.81 to 0.90) than non-diabetic individuals not on the drug, a finding that has fueled the TAME trial rationale.

What to Do If WellCare Denies Metformin Coverage

Denials are uncommon for standard diabetes indications but can happen due to formulary errors, billing code mismatches, or off-label use. The appeals process has five levels.

Level 1: Coverage Determination and Redetermination

If a claim is denied at the pharmacy, your prescriber can request a coverage determination. WellCare must issue a decision within 72 hours (standard) or 24 hours (expedited). If denied, you can request a redetermination from WellCare within 60 days of the denial notice. WellCare has 7 days (standard) or 72 hours (expedited) to respond, per 42 CFR 423.590.

Levels 2 Through 5: External Review

If WellCare upholds the denial, the case moves to an Independent Review Entity (IRE) contracted by CMS, then to the Office of Medicare Hearings and Appeals (OMHA), then the Medicare Appeals Council, and finally federal district court. The CMS Medicare Appeals process overview details timelines and filing requirements for each level.

For most metformin denials, the issue resolves at Level 1 or Level 2 once a prescriber submits documentation confirming a valid diabetes or prediabetes diagnosis.

Alternatives If WellCare Does Not Cover Your Specific Metformin Formulation

Even in the uncommon scenario where a specific formulation is not covered, several options exist.

GoodRx and Manufacturer Programs

GoodRx coupons frequently price metformin IR 1,000 mg (60 tablets) at $4 to $9 at major pharmacy chains regardless of insurance. Because the drug is so inexpensive, some patients find that paying cash is simpler than navigating a formulary exception.

Metformin has no manufacturer patient assistance program (PAP) because it is a generic with no brand-name sponsor active in the US market. The FDA's drug shortage database confirms no current shortage of metformin HCl.

Formulary Exception Request

If your physician believes you need metformin ER specifically and WellCare covers only IR, a formulary exception can be requested citing medical necessity (gastrointestinal intolerance to IR). The CMS Formulary Exception guidance requires WellCare to evaluate exceptions on a case-by-case basis within the same timelines as PA decisions.

Metformin Safety Profile and Contraindications Relevant to Coverage Decisions

Understanding why a coverage decision might cite safety criteria helps you respond more effectively.

Renal Function and eGFR Thresholds

The FDA updated the metformin label in 2016 to replace the serum creatinine-based contraindication with an eGFR-based threshold. Metformin is contraindicated when eGFR falls below 30 mL/min/1.73 m2 and dose reduction is recommended when eGFR is 30 to 45 mL/min/1.73 m2, per the FDA Drug Safety Communication (2016). This change expanded access for patients with moderate kidney disease who were previously excluded.

If WellCare receives a claim for a patient with a documented eGFR <30, the plan's utilization management system may flag it. The fix is a prescriber note documenting a current eGFR above 30 or documenting clinical justification for the exception.

Lactic Acidosis: Rare but Cited in Denials

Lactic acidosis occurs at an estimated rate of approximately 3 cases per 100,000 patient-years, based on a Cochrane systematic review (Salpeter et al., 2010) that found no statistically significant increase in lactic acidosis risk with metformin compared to other antidiabetic treatments (risk ratio 0.80, 95% CI 0.26 to 2.45, P<0.001 was not reached for excess harm). Despite this reassuring data, some PA forms still list lactic acidosis as a risk requiring documentation of normal renal function.

Vitamin B12 Monitoring

Long-term metformin use reduces vitamin B12 absorption in 10 to 30 percent of patients by inhibiting calcium-dependent ileal B12 absorption, per data from the Diabetes Prevention Program Outcomes Study (DPPOS) which found a 19 percent prevalence of B12 deficiency in long-term metformin users vs. 10 percent in placebo users (P<0.001). The ADA 2024 Standards of Care, Section 9 recommends periodic B12 monitoring in patients on long-term metformin. This does not affect coverage but is clinically relevant for HealthRX patients on longevity protocols.

How to Verify Your Specific WellCare Plan's Metformin Coverage Right Now

Formulary details change annually, and this article reflects general patterns rather than your specific plan's 2025 benefits.

Three Verification Methods

Method 1: WellCare Online Formulary Search. Go to WellCare.com, select your plan, and use the drug search tool. Enter "metformin" and your dosage. The tool displays your tier, copay, and any coverage restrictions in real time.

Method 2: Call Member Services. Dial 1-800-903-5253 (TTY 711), available Monday through Friday 8 a.m. To 8 p.m. Local time. Ask specifically: (a) the tier for your exact formulation and dose, (b) whether a deductible applies to that tier, (c) whether any PA or quantity limits apply, and (d) the preferred pharmacy network for lowest cost-sharing.

Method 3: Review Your Evidence of Coverage Document. WellCare mails the annual EOC each fall. The formulary appendix lists every covered drug, its tier, and any restrictions. The CMS requirement for EOC delivery mandates that enrollees receive this document by October 15 for the upcoming plan year.

Metformin in the Context of GLP-1 and Combination Therapy Coverage

Many patients asking about metformin coverage are also considering or already taking GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound). These drugs occupy higher tiers and carry significantly higher costs.

Combination Therapy: Clinical Rationale

The UKPDS 34 trial (N=1,704) established that metformin monotherapy in overweight type 2 diabetes patients reduced all-cause mortality by 36 percent and diabetes-related death by 42 percent vs. Conventional treatment over a median of 10.7 years. Metformin remains the foundation on which newer agents are added, not replaced. The ADA and the European Association for the Study of Diabetes (EASD) 2022 Consensus Report recommend continuing metformin when initiating GLP-1 therapy unless contraindicated.

WellCare Coverage of GLP-1 Agents vs. Metformin

GLP-1 agonists for diabetes (Ozempic, Trulicity) typically appear on Tier 3 or Tier 4 of WellCare Part D formularies with copays of $35 to $100 per month after meeting deductible requirements. GLP-1 agents approved solely for weight loss (Wegovy, Zepbound) are not covered by Medicare Part D under current law, per Section 1860D-2(e)(2)(A) of the Social Security Act, which excludes drugs used for weight loss from Part D coverage. Metformin's low cost and broad coverage make it a practical anchor for combination regimens.